Decheng Capital Management III (Cayman), LLC - NEUBASE THERAPEUTICS INC ownership

NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 1 filers reported holding NEUBASE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Decheng Capital Management III (Cayman), LLC ownership history of NEUBASE THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$92,500
-50.0%
50,000
-95.0%
0.03%
-61.3%
Q1 2023$185,000
-2.7%
1,000,0000.0%0.08%
+5.6%
Q4 2022$190,200
-51.8%
1,000,0000.0%0.07%
-50.3%
Q3 2022$395,000
-62.4%
1,000,0000.0%0.14%
-64.1%
Q2 2022$1,050,000
-44.1%
1,000,0000.0%0.40%
-30.9%
Q1 2022$1,880,0001,000,0000.58%
Other shareholders
NEUBASE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Greenlight Capital 2,027,027$14,169,0000.85%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 103,500$723,0000.55%
Sio Capital Management, LLC 293,699$2,053,0000.42%
GSA CAPITAL PARTNERS LLP 121,389$849,0000.14%
Frontier Wealth Management LLC 145,000$1,014,0000.08%
PRELUDE CAPITAL MANAGEMENT, LLC 311,000$2,174,0000.06%
Oak Grove Capital LLC 19,175$134,0000.04%
PREMIER ASSET MANAGEMENT LLC 14,977$105,0000.02%
Trexquant Investment LP 15,479$108,0000.01%
PILLAR PACIFIC CAPITAL MANAGEMENT LLC 19,800$138,0000.01%
View complete list of NEUBASE THERAPEUTICS INC shareholders